| Gene Symbol | ent-prot-1e3aff6a |
| AD diagnosis confirmation | Differentiating AD from other dementias |
| Disease staging | Tracking NFT progression using Braak staging in vivo |
| Prognostication | Predicting cognitive decline trajectory |
| Therapeutic monitoring | Assessing anti-tau therapy efficacy |
| Clinical trial enrichment | Selecting tau-positive patients |
| Binding specificity | High affinity for paired helical filament (PHF) tau in AD |
| Approved indication | Amyloid-positive adults with MCI or dementia due to AD |
| Acquisition timing | 80-100 minutes post-injection |
| Limitations | Off-target binding in basal ganglia, choroid plexus; limited binding to 3R/4R tauopathies |
| Databases | GeneCardsUniProtNCBI GeneHPASTRING |